Matches in SemOpenAlex for { <https://semopenalex.org/work/W2791911315> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2791911315 endingPage "149" @default.
- W2791911315 startingPage "147" @default.
- W2791911315 abstract "The approved combination of nivolumab and ipilimumab has demonstrated potent efficacy in the treatment of metastatic melanoma, with higher objective response rates (ORRs) and progression-free survival (PFS) as first-line treatment than either agent alone [ 1 Postow M.A. Chesney J. Pavlick A.C. Robert C. Grossmann K. McDermott D. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015; 372: 2006-2017https://doi.org/10.1056/NEJMoa1414428 Crossref PubMed Scopus (2097) Google Scholar , 2 Larkin J. Hodi F.S. Wolchok J.D. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373: 1270-1271https://doi.org/10.1056/NEJMc1509660 Crossref PubMed Scopus (556) Google Scholar ] and improvement of 3-year overall survival (OS) compared with ipilimumab [ [3] Wolchok J.D. Chiarion-Sileni V. Gonzalez R. Rutkowski P. Grob J.-J. Cowey C.L. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017; 377: 1345-1356https://doi.org/10.1056/NEJMoa1709684 Crossref PubMed Scopus (2206) Google Scholar ]. However, few studies have evaluated the efficacy in patients with primary resistance to PD-1 inhibitors [ 4 Ugurel S. Kiecker F. Fröhling S. Wetter A. Bankfalvi A. Sucker A. et al. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma. Eur J Cancer Oxf Engl 1990. 2017; 83: 142-145https://doi.org/10.1016/j.ejca.2017.06.020 Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar , 5 Kirchberger M.C. Hauschild A. Schuler G. Heinzerling L. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma. Eur J Cancer Oxf Engl 1990. 2016; 65: 182-184https://doi.org/10.1016/j.ejca.2016.07.003 Abstract Full Text Full Text PDF PubMed Scopus (30) Google Scholar , 6 Spain L. Schmid T. Gore M. Larkin J. Efficacy of the combination of ipilimumab and nivolumab following progression on pembrolizumab in advanced melanoma with poor risk features. Eur J Cancer Oxf Engl 1990. 2017; 75: 243-244https://doi.org/10.1016/j.ejca.2016.12.040 Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar , 7 Zimmer L. Apuri S. Eroglu Z. Kottschade L.A. Forschner A. Gutzmer R. et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer Oxf Engl 1990. 2017; 75: 47-55https://doi.org/10.1016/j.ejca.2017.01.009 Abstract Full Text Full Text PDF PubMed Scopus (117) Google Scholar ], and the usefulness and safety profile after anti-CTLA4 and/or anti-PD1 failure is still unclear. Moreover, no data are available in patients who have progressed after targeted therapy but who have never been treated by single-agent immunotherapy. In a multicenter retrospective study, we assess the efficacy and safety of combined nivolumab and ipilimumab therapy in advanced melanoma in first-line treatment compared with after sequential anti-CTLA4 and/or anti-PD1 failure or after targeted therapy failure." @default.
- W2791911315 created "2018-03-29" @default.
- W2791911315 creator A5006200908 @default.
- W2791911315 creator A5007002871 @default.
- W2791911315 creator A5009968141 @default.
- W2791911315 creator A5015446939 @default.
- W2791911315 creator A5025478490 @default.
- W2791911315 creator A5028528715 @default.
- W2791911315 creator A5055627811 @default.
- W2791911315 creator A5067794998 @default.
- W2791911315 creator A5082278497 @default.
- W2791911315 creator A5089297467 @default.
- W2791911315 date "2018-04-01" @default.
- W2791911315 modified "2023-10-18" @default.
- W2791911315 title "Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma" @default.
- W2791911315 cites W2128758225 @default.
- W2791911315 cites W2166662937 @default.
- W2791911315 cites W2753432434 @default.
- W2791911315 doi "https://doi.org/10.1016/j.ejca.2018.01.062" @default.
- W2791911315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29449059" @default.
- W2791911315 hasPublicationYear "2018" @default.
- W2791911315 type Work @default.
- W2791911315 sameAs 2791911315 @default.
- W2791911315 citedByCount "10" @default.
- W2791911315 countsByYear W27919113152019 @default.
- W2791911315 countsByYear W27919113152020 @default.
- W2791911315 countsByYear W27919113152021 @default.
- W2791911315 countsByYear W27919113152022 @default.
- W2791911315 countsByYear W27919113152023 @default.
- W2791911315 crossrefType "journal-article" @default.
- W2791911315 hasAuthorship W2791911315A5006200908 @default.
- W2791911315 hasAuthorship W2791911315A5007002871 @default.
- W2791911315 hasAuthorship W2791911315A5009968141 @default.
- W2791911315 hasAuthorship W2791911315A5015446939 @default.
- W2791911315 hasAuthorship W2791911315A5025478490 @default.
- W2791911315 hasAuthorship W2791911315A5028528715 @default.
- W2791911315 hasAuthorship W2791911315A5055627811 @default.
- W2791911315 hasAuthorship W2791911315A5067794998 @default.
- W2791911315 hasAuthorship W2791911315A5082278497 @default.
- W2791911315 hasAuthorship W2791911315A5089297467 @default.
- W2791911315 hasConcept C121608353 @default.
- W2791911315 hasConcept C126322002 @default.
- W2791911315 hasConcept C143998085 @default.
- W2791911315 hasConcept C2777658100 @default.
- W2791911315 hasConcept C2777701055 @default.
- W2791911315 hasConcept C2780030458 @default.
- W2791911315 hasConcept C2781433595 @default.
- W2791911315 hasConcept C2994587330 @default.
- W2791911315 hasConcept C502942594 @default.
- W2791911315 hasConcept C71924100 @default.
- W2791911315 hasConceptScore W2791911315C121608353 @default.
- W2791911315 hasConceptScore W2791911315C126322002 @default.
- W2791911315 hasConceptScore W2791911315C143998085 @default.
- W2791911315 hasConceptScore W2791911315C2777658100 @default.
- W2791911315 hasConceptScore W2791911315C2777701055 @default.
- W2791911315 hasConceptScore W2791911315C2780030458 @default.
- W2791911315 hasConceptScore W2791911315C2781433595 @default.
- W2791911315 hasConceptScore W2791911315C2994587330 @default.
- W2791911315 hasConceptScore W2791911315C502942594 @default.
- W2791911315 hasConceptScore W2791911315C71924100 @default.
- W2791911315 hasLocation W27919113151 @default.
- W2791911315 hasLocation W27919113152 @default.
- W2791911315 hasOpenAccess W2791911315 @default.
- W2791911315 hasPrimaryLocation W27919113151 @default.
- W2791911315 hasRelatedWork W2745358348 @default.
- W2791911315 hasRelatedWork W2752773766 @default.
- W2791911315 hasRelatedWork W2773756552 @default.
- W2791911315 hasRelatedWork W2888298425 @default.
- W2791911315 hasRelatedWork W2891051134 @default.
- W2791911315 hasRelatedWork W2932851203 @default.
- W2791911315 hasRelatedWork W2963333658 @default.
- W2791911315 hasRelatedWork W3109496017 @default.
- W2791911315 hasRelatedWork W4361939003 @default.
- W2791911315 hasRelatedWork W2158539401 @default.
- W2791911315 hasVolume "93" @default.
- W2791911315 isParatext "false" @default.
- W2791911315 isRetracted "false" @default.
- W2791911315 magId "2791911315" @default.
- W2791911315 workType "article" @default.